nk-121 and Carcinoma--Squamous-Cell

In order to exploit the optimal administration schedules of newly synthesized analogues of cisplatin (NK121) and bleomycin (NK313), antitumor effects of three different injection schedules, namely (A) an injection every fourth day for 3 times in 9 days, (B) once daily injection for 9 days, and (C) continuous infusion for 5 days, were examined in nude mice bearing human squamous cell carcinoma. The tumor growth delay was employed as an experimental endpoint. Antitumor effects of both analogues showed schedule dependencies showing the highest effect with schedule (A) of NK121 and schedule (C) of NK313, respectively. In the combination chemotherapy of NK121 with NK313, the highest antitumor effect was observed when mice were given NK121 by schedule (A) followed by NK313 by schedule(C). This combination sequence also was less toxic with respect to the change of the body weight, while simultaneous treatment was with weak clinical significance because of its low antitumor activity and severe toxicity.

Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Screening Assays, Antitumor; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation

Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Line; Cisplatin; Humans; In Vitro Techniques; Lung Neoplasms; Organoplatinum Compounds; Tumor Cells, Cultured; Tumor Stem Cell Assay

Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; Fluorouracil; Humans; In Vitro Techniques; Organoplatinum Compounds; Pharyngeal Neoplasms; Tumor Cells, Cultured

Topics: Animals; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Female; Head and Neck Neoplasms; Mice; Mice, Nude; Organoplatinum Compounds